Three neuromodulation therapies have been appropriately tested and approved in refractory
focal epilepsies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior …

Introduction: Epilepsy affects more than 1% of the US population, and over 30% of adults
with epilepsy do not respond to antiseizure medications without life-impacting medication …

Objectives Up to 40% of patients with idiopathic generalised epilepsy (IGE) are drug
resistant and potentially could benefit from intracranial neuromodulation of the seizure …

Three neuromodulation therapies, all using implanted device and electrodes, have been
approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve …

The cyclical organization of seizures in epilepsy has been described since antiquity.
However, historical explanations for seizure cycles—based on celestial, hormonal, and …

Objective The aim of the study was to determine if corticothalamic responsive stimulation
targeting the centromedian nucleus of the thalamus (CMT) is a potential treatment for …

Introduction Implanted neurostimulation devices are gaining traction as therapeutic options
for people with certain forms of drug-resistant focal epilepsy. Some of these devices enable …

Objective Based on the promising results of randomized controlled trials, deep brain
stimulation (DBS) and responsive neurostimulation (RNS) are used increasingly in the …

Nearly 1% of the global population suffers from epilepsy. Drug‐resistant epilepsy (DRE)
affects one‐third of epileptic patients who are unable to treat their condition with existing …

The cyclical structure of epilepsy was recently (re)-discovered through years-long
intracranial electroencephalography (EEG) obtained with implanted devices. In this review …